Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074719 | 0.85 | TAAR1 (0.34) | TAAR1HRH3CA12CA1CA2 | |
| SCHEMBL11696212 | 0.81 | CYP4F2 (0.38) | CD274CA12CA2CA3CA4 | |
| SCHEMBL11695329 | 0.78 | KDM4E (0.41) | TAAR1CA12CA1CA2CA4 | |
| SCHEMBL7979213 | 0.78 | CNR1 (0.39) | TAAR1GSK3B | |
| SCHEMBL11696742 | 0.78 | TAAR1 (0.55) | TAAR1PNMT | |
| SCHEMBL11693754 | 0.77 | HRH3 (0.39) | TAAR1HRH3 | |
| SCHEMBL3686388 | 0.77 | MAPT (0.53) | GSK3B | |
| SCHEMBL11695006 | 0.77 | GABRA1 (0.40) | TAAR1 | |
| SCHEMBL11695911 | 0.77 | IDH1 (0.42) | CA1CA2 | |
| SCHEMBL1641530 | 0.75 | CALM1 (0.35) | CA2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422235-B2 | Sulfonamide derivatives with therapeutic indications | PHARMOS CORPORATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | disclosed |
| EP-2139852-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | Pharmos Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008075353-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| US-7338954-B2 | Compounds useful as motilin agonists and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-7262195-B2 | Compounds useful as motilin agonists and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-28 | — | — | US | disclosed |
| US-20050080116-A1 | Compounds useful as motilin agonists and method | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
| WO-2005027908-A1 | COMPOUNDS USEFUL AS MOTILIN AGONISTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005027637-A1 | COMPOUNDS USEFUL AS MOTILIN AGONISTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065156-A1 | Compounds useful as motilin agonists and method | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | SULT2A1, STS, SULT1A1 | TAAR1 2966/4885HRH3 1160/4885CD274 4637/4885 |
| US-20050080116-A1 | Compounds useful as motilin agonists and method | MLNR, SSTR3, HRH4 | TAAR1 249/4885HRH3 7/4885CD274 4431/4885 |
| US-20050065156-A1 | Compounds useful as motilin agonists and method | MLNR, SSTR3, HRH2 | TAAR1 289/4885HRH3 6/4885CD274 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.